| Autor: |
Tsukasa, KURIMOTO, Naomasa, ASAKA, Toshimatsu, MAEDA, Kenji, IRIMURA, Naosuke, MATSUURA |
| Přispěvatelé: |
大鵬薬品工業株式会社 製薬センター 薬理研究所, Sec of Pharmacology Research Lab. TOKUSHIMA RESEARCH CENTER TAIHO PHARMACEUTICAL CO., LTD. |
| Jazyk: |
angličtina |
| Rok vydání: |
2000 |
| Předmět: |
|
| Zdroj: |
岐阜藥科大學紀要 = The annual proceedings of Gifu College of Pharmacy. 49:45-52 |
| Popis: |
MET-88,an inhibitor of γ-butyrobetaine hydroxylase, can be characterized as a unique cardioprotective agent for the treatment of congestive heart failure (CHF) with an ability to regulate the activity of SR Ca^-ATPase. MET-88 protected the hypoxic and ischemic myocardium due to the modulation of myocardial metabolism and improved cardiac remodeling and hypertrophy as effectively as captopril. MET-88 also increased the failed Ca^-ATPase activity in the Sarcoplastic reticulum (SR), which increase might have resulted from ATP synthesis through glycolysis. These effects of MET-88 may be expected to improve mortality, prognosis, and exercise intolerance in CHF patients. In summary, MET-88 may be a useful drug for the treatment of CHF. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
